Immune repertoire sequencing is extensively used in biomarker discovery to improve the success rate and cost-effectiveness of rational drug development. For instance, in November, 2017, the Center for Commercialization of Cancer Immunotherapy (C3i) started offering T cell receptor-beta sequencing services in its Biomarker and Diagnostic unit in Canada. Increasing demand for personalized medicine, in turn, is expected to aid the immune repertoire sequencing market growth, as personalized medicine uses an individual’s genetic profile to guide decisions made in regard to the diagnosis, prevention, and treatment of diseases.
The global immune repertoire sequencing market size was valued at US$ 114.3 million in 2017, and is expected to witness a CAGR of 5.6% over the forecast period (2018 – 2026).
Increasing Research & Development and Demand for Genomic and Repertoire Sequencing-based Research is expected to Drive Growth of the Immune Repertoire Sequencing Market
Increasing research and development and launches of novel products by key players are expected to be the major driving force for global immune repertoire sequencing market growth in the near future. For instance, in 2016, ArcherDX, Inc. expanded its product portfolio with the launch of Archer Immunoverse immune repertoire sequencing assays at the American Society of Hematology (ASH). In 2017, ArcherDX, Inc. launched Archer Immunoverse B Cell Receptor (BCR) assays to characterize the human B cell repertoire.
According to a study published by Cold Spring Harbor Laboratory, in 2017, researchers from Stanford University applied immune repertoire sequencing to identify disease-related signatures in the immune systems of patients with systemic sclerosis-related pulmonary hypertension (SSc-PAH), a rare chronic autoimmune disease that affects the connective tissue. Therefore, increasing research on immune repertoire sequencing is expected to create a favorable environment for immune repertoire sequencing market growth in the near future.
Immune Repertoire Sequencing Market – Regional Insights
On the basis of region, the global immune repertoire sequencing market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold a dominant position in the global immune repertoire sequencing market during the forecast period, owing to high presence of key industry players in the region (including Illumina Inc., Thermo Fisher Scientific, Pacific Biosciences, and CD Genomics). These players are increasingly focusing on development of novel technologies for immune repertoire sequencing. For instance, in 2017, 10x Genomics Inc., U.S. based company, added B-Cell and 5’Unbiased Enrichment Kit to its chromium immune repertoire profiling solution or immune repertoire sequencing.
Download PDF Brochure of This Business Report @ https://www.coherentmarketinsights.com/insight/request-pdf/1517
Immune Repertoire Sequencing Market – Competitive Landscape
Key players operating in the global immune repertoire sequencing market include Thermo Fisher Scientific, Inc., Illumina Inc., ArcherDX, Inc., Roche Holding AG, Pacific Biosciences, CD Genomics, Atreca, Inc., Adaptive Biotechnologies, Oxford Nanopore Technologies, Ltd., Qiagen N.V., Agilent Technologies, Inc., and Takara Bio, Inc.